ArticleAntimicrobial agents and chemotherapy2005
Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure.
Article in Antimicrobial agents and chemotherapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 54 citations in OpenAlex.
- Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis.Antimicrobial agents and chemotherapy · 2009Trial
- Correlation of the pharmacokinetic parameters of amikacin and ceftazidime.Clinical pharmacokinetics · 2007Trial
- Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection.Antimicrobial agents and chemotherapy · 2006Trial
- Predictors of mortality and progression from colonization to Stenotrophomonas maltophilia bloodstream infection in hematologic disorders: a single-center retrospective study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- The Dutch Working Party on Antibiotic Policy (SWAB) Recommendations for the Diagnosis and Management of Febrile Neutropenia in Patients with Cancer.Infectious diseases and therapy · 2022Article
- Understanding and Managing Sepsis in Patients With Cancer in the Era of Antimicrobial Resistance.Frontiers in medicine · 2021Review
- Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interventional study.The Journal of antimicrobial chemotherapy · 2020Article
- Article
- Article
- The prevention and management of infections due to multidrug resistant organisms in haematology patients.British journal of clinical pharmacology · 2015Review
- Altered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancy.Antimicrobial agents and chemotherapy · 2014Article
- Vancomycin dosing in neutropenic patients.PloS one · 2014Observational
- Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.Clinical pharmacokinetics · 2013Review
- Antibiotic therapy in hematological neutropenic patients: what is the news?Leukemia supplements · 2012Article
- High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function.Antimicrobial agents and chemotherapy · 2010Article
- Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.Antimicrobial agents and chemotherapy · 2009Article
- Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?Critical care (London, England) · 2009Review
- Optimizing therapy with antibacterial agents: use of pharmacokinetic-pharmacodynamic principles in pediatrics.Paediatric drugs · 2007Review
- Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.Clinical pharmacokinetics · 2007Review
- Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.Clinical pharmacokinetics · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pharmacokinetic-pharmacodynamic profile of a fixed 6-g daily continuous intravenous infusion of ceftazidime was assessed in 20 febrile neutropenic patients with acute myeloid leukemia. Mean steady-state ceftazidime concentrations averaging 40 mg/liter from day 2 on ensured maximized pharmacodynamic exposure (values close to four to five times the MIC breakpoint against Pseudomonas aeruginosa). However, large intra- and interindividual pharmacokinetic variability was documented throughout the study period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.